WallStreetZenWallStreetZen

NASDAQ: ATXS
Astria Therapeutics Inc Stock

$10.89+0.08 (+0.74%)
Updated Apr 15, 2024
ATXS Price
$10.89
Fair Value Price
$5.82
Market Cap
$597.89M
52 Week Low
$4.26
52 Week High
$16.90
P/E
-4.5x
P/B
2.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$72.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$68M
Beta
0.82
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATXS Overview

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATXS ($10.89) is overvalued by 87.06% relative to our estimate of its Fair Value price of $5.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATXS ($10.89) is not significantly undervalued (87.06%) relative to our estimate of its Fair Value price of $5.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATXS due diligence checks available for Premium users.

Be the first to know about important ATXS news, forecast changes, insider trades & much more!

ATXS News

Valuation

ATXS fair value

Fair Value of ATXS stock based on Discounted Cash Flow (DCF)
Price
$10.89
Fair Value
$5.82
Overvalued by
87.06%
ATXS ($10.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATXS ($10.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATXS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.5x
Industry
14.94x
Market
41.94x

ATXS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.46x
Industry
5.88x
ATXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATXS's financial health

Profit margin

Revenue
$0.0
Net Income
-$31.4M
Profit Margin
0%
ATXS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$254.7M
Liabilities
$11.6M
Debt to equity
0.05
ATXS's short-term assets ($250.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATXS's short-term assets ($250.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATXS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$30.2M
Investing
-$2.0M
Financing
$88.0M
ATXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATXS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATXS$597.89M+0.74%-4.50x2.46x
KRRO$596.59M-0.81%-1.40x3.51x
ALLO$600.28M-6.58%-1.70x1.17x
CVAC$593.29M-8.93%-1.69x0.93x
VALN$590.38M-0.12%-5.36x4.24x

Astria Therapeutics Stock FAQ

What is Astria Therapeutics's quote symbol?

(NASDAQ: ATXS) Astria Therapeutics trades on the NASDAQ under the ticker symbol ATXS. Astria Therapeutics stock quotes can also be displayed as NASDAQ: ATXS.

If you're new to stock investing, here's how to buy Astria Therapeutics stock.

What is the 52 week high and low for Astria Therapeutics (NASDAQ: ATXS)?

(NASDAQ: ATXS) Astria Therapeutics's 52-week high was $16.90, and its 52-week low was $4.26. It is currently -35.56% from its 52-week high and 155.63% from its 52-week low.

How much is Astria Therapeutics stock worth today?

(NASDAQ: ATXS) Astria Therapeutics currently has 54,903,061 outstanding shares. With Astria Therapeutics stock trading at $10.89 per share, the total value of Astria Therapeutics stock (market capitalization) is $597.89M.

Astria Therapeutics stock was originally listed at a price of $780.00 in Jun 25, 2015. If you had invested in Astria Therapeutics stock at $780.00, your return over the last 8 years would have been -98.6%, for an annualized return of -41.37% (not including any dividends or dividend reinvestments).

How much is Astria Therapeutics's stock price per share?

(NASDAQ: ATXS) Astria Therapeutics stock price per share is $10.89 today (as of Apr 15, 2024).

What is Astria Therapeutics's Market Cap?

(NASDAQ: ATXS) Astria Therapeutics's market cap is $597.89M, as of Apr 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Astria Therapeutics's market cap is calculated by multiplying ATXS's current stock price of $10.89 by ATXS's total outstanding shares of 54,903,061.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.